SIROMED PHARMA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 10,258,000 | 9,321,000 | 10,675,000 | 10,324,000 | 11,745,000 | 11,011,000 | 11,422,000 | 11,996,000 |
| Profit before tax | 100,000 | 214,000 | 198,000 | 209,000 | 218,000 | 33,000 | 167,000 | 328,200 |
| Net profit | - | - | - | - | 178,000 | 5,000 | 126,000 | 252,200 |
| Equity | 648,000 | 825,000 | 989,000 | 1,163,000 | 1,341,000 | 1,346,000 | 1,472,000 | 1,724,500 |
| Liabilities | - | - | - | - | 5,526,000 | 6,104,000 | 5,429,000 | - |
| Non-current assets | 33,000 | 106,000 | 192,000 | 203,000 | 171,000 | 147,000 | 252,000 | 233,000 |
| Current assets | 4,770,000 | 4,707,000 | 5,355,000 | 6,096,000 | 6,696,000 | 7,303,000 | 6,649,000 | - |
| Total assets | 4,803,000 | 4,813,000 | 5,547,000 | 6,299,000 | 6,867,000 | 7,450,000 | 6,901,000 | 233,000 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 378,177 | 494,506 | 495,716 |
| Social insurance contributions | - | - | - | - | - | 123,760 | 117,050 | 119,323 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +28.7% | -9.1% | +14.5% | -3.3% | +13.8% | -6.2% | +3.7% | +5.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | - | - | - | 2.6% | 0.1% | 1.8% | 108.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | 13.3% | 0.4% | 8.6% | 14.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | 1.5% | 0.0% | 1.1% | 2.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 1.0% | 2.3% | 1.9% | 2.0% | 1.9% | 0.3% | 1.5% | 2.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 4.1 | 4.5 | 3.7 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 809,840 | 771,395 | 859,729 | 692,110 | 824,211 | 800,800 | 878,615 | 1,028,226 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
SIROMED PHARMA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-02-17 | 2023-02-20 | 3136.96 |
| 2022-05-17 | 2022-05-29 | 221.92 |
| 2022-03-16 | 2022-04-14 | 0.46 |
| 2022-02-17 | 2022-03-14 | 0.46 |
| 2021-12-30 | 2022-01-02 | 0.11 |
| 2021-12-29 | 2021-12-29 | 0.07 |
| 2021-12-17 | 2021-12-28 | 0.08 |
| 2021-12-16 | 2021-12-16 | 0.07 |
| 2021-11-22 | 2021-12-14 | 0.07 |
| 2021-11-19 | 2021-11-21 | 0.06 |
| 2021-11-16 | 2021-11-18 | 0.05 |
SIROMED PHARMA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-02-28 | 2025-02-28 | 7.49 |
| 2025-02-21 | 2025-02-25 | 7.49 |
| 2025-01-30 | 2025-02-10 | 19.65 |
| 2024-11-27 | 2024-11-28 | 11620.64 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
SIROMED PHARMA, UAB (code 304039854) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €12.00M, up 5.0% year on year and 8.9% over two years. Net profit rose to €252.2K from €126.0K in 2024 and €5.0K in 2023, showing a clear improvement in profitability across the three-year period. The net profit margin increased from 0.0% in 2023 to 1.1% in 2024 and 2.1% in 2025. At year-end 2025, total assets stood at €7.14M, with equity of €1.72M and liabilities of €5.41M. The equity ratio was 24.2%, while debt-to-equity was 3.14. Asset turnover was 1.68x, indicating efficient use of the asset base in relation to revenue. Profitability ratios were also positive, with ROE at 14.6% and ROA at 3.5%. Revenue per employee was €1.09M and profit per employee was €22.9K, reflecting strong productivity in the latest financial year.